西班牙公司ESTEVE获得Caprelsa的权利,这是一种治疗甲状腺癌的药物。 Spanish firm ESTEVE acquires rights to Caprelsa®, a drug treating medullary thyroid cancer.

西班牙ESTEVE公司从Sanofi获得Caprelsa(vandetanib)的权利,这是一种用于治疗5岁以上成人和儿童甲状腺癌的药物。 Spanish company ESTEVE has acquired rights to Caprelsa® (vandetanib) from Sanofi, a drug used to treat medullary thyroid cancer in adults and children over 5. Caprelsa 工作方式是堵塞向癌症细胞提供血液的酶,减缓癌症增长。 Caprelsa® works by blocking enzymes that supply blood to cancer cells, slowing cancer growth. 这一举动符合ESTEVE扩大其专门治疗战略,以满足50多个国家的重大医疗需要。 This move aligns with ESTEVE’s strategy to expand its specialized treatments for significant medical needs, covering more than 50 countries.